Core Viewpoint - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 0.79% and the Hang Seng Tech Index dropping by 1.76% [1] Market Performance - The Hong Kong stock market closed with the Hang Seng Index down 0.79% and the Hang Seng Tech Index down 1.76% [1] - The Hong Kong Tech ETF (159751) decreased by 1.99%, while the Hang Seng Hong Kong Stock Connect ETF (159318) fell by 0.49% [1] Sector Performance - The telecommunications equipment sector showed the highest gains, while the container and packaging, as well as building products sectors, experienced the largest declines [1] Individual Stock Movements - Notable gainers included: - Innovent Biologics up 7.81% - Kelun-Bio up 6.26% - China National Pharmaceutical Group up 5.78% - Weichai Power up 4.49% - Hansoh Pharmaceutical up 4.21% [1] - Significant decliners included: - Times Electric down 12.15% - Lion Group Holdings down 20.29% [1] - Other notable gainers: - Spring Medical up 14.04% - 3SBio up 11.27% [1]

Group 1 - The core view of the report indicates that the pharmaceutical and biotechnology industry is expected to continue thriving, particularly in the innovative drug sector, driven by the rise of domestic innovative drugs and supportive policies [2][4][23] - The report highlights that from the beginning of 2025 to October 23, the pharmaceutical index increased by 23%, while the Hang Seng Biotechnology Index surged by 82%, with many A+H shares experiencing over 100% growth [2][16] - The report identifies the sub-industries with the most potential for investment in 2026, ranking them as follows: innovative drugs > CXO and research upstream > medical devices > medical services > traditional Chinese medicine > pharmacies [2][4] Group 2 - The report emphasizes that the international academic standing of Chinese companies has significantly improved, with a notable presence at major conferences such as ASCO and ESMO, showcasing the advancements in innovative drugs [4][11] - The report notes that the number and value of license-out deals for innovative drugs have reached new highs, with 103 deals totaling $92.03 billion in the first three quarters of 2025, marking a 77% year-on-year increase [4][11] - The report discusses the expected growth in global R&D investment, projected to rise from $277.6 billion in 2024 to $476.1 billion by 2030, indicating a robust upward trend in the CXO sector [4][11] Group 3 - The report highlights the medical device sector as being at a low valuation point, with significant potential for growth driven by innovation, self-sufficiency, and international expansion [4][11] - The report mentions that the global medical device market is continuously developing, with domestic manufacturers expanding overseas and the domestic market for medical equipment procurement expected to gradually recover [4][11] - The report recommends specific companies for investment, including innovative drug firms and those involved in medical devices, such as 恒瑞医药 (Hengrui Medicine), 信立泰 (Sino Biopharmaceutical), and 迈瑞医疗 (Mindray) [4][11]

Group 1 - The report suggests that the Hong Kong stock market is entering an adjustment phase at the end of the year, but it remains in a long-term upward trend [1] - The report emphasizes a continued positive outlook on AI technology, predicting a marginal recovery in Hong Kong's EPS in the first quarter of next year [2] - There is an increased allocation towards dividend stocks due to a decline in market sentiment and a historical trend showing higher win rates for dividend stocks in November and December [2] - The report maintains a favorable view on innovative pharmaceuticals, citing benefits from potential Federal Reserve interest rate cuts and a clear trend in the innovative drug industry [2] Group 2 - The report lists a selection of "golden stocks" with detailed financial metrics, including Alibaba, XPeng Motors, CICC, Shenzhou International, Innovent Biologics, Kelun-Biotech, 3SBio, Gree Power, Sinopec, and Guoquan [3][8] - Alibaba is highlighted for its leadership in AI and cloud computing, with significant revenue growth expected from its cloud business [11][12] - XPeng Motors is projected to achieve substantial revenue growth, with a focus on developing a platform for mass-market vehicles [17][19] - CICC is expected to benefit from a recovering IPO market and increased trading activity, enhancing its competitive position in investment banking and wealth management [24][26] - Shenzhou International is anticipated to see sales growth driven by strong demand from major clients like Adidas and Nike [30][32] - Innovent Biologics is expected to achieve profitability in 2025, with a strong pipeline of innovative drugs [35][40] - Kelun-Biotech is advancing its clinical trials and commercialization efforts, maintaining a positive outlook [44][46] - 3SBio is positioned for growth with its innovative drug pipeline and international expansion [48][50] - Gree Power is expected to improve its financial performance through increased cash flow and dividend potential [52][56] - Sinopec is focusing on upstream exploration and development, with a strong outlook for its natural gas segment [60][62] - Guoquan is experiencing improved same-store sales and expansion in rural areas, indicating strong operational capabilities [66][68]

Core Insights - The Hong Kong Stock Connect Innovative Drug ETF (520880) experienced a decline, with a drop of 2% during intraday trading, despite a significant inflow of funds totaling over 218 million yuan in the past ten days [1] - The ETF covers 37 innovative drug companies, with over 30 stocks showing negative performance, including major players like 3SBio and CanSino Biologics, which fell more than 3% [1] - The recent conclusion of the medical insurance negotiation and commercial insurance innovative drug directory price discussions is expected to enhance growth opportunities for innovative drug companies [1] Fund Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) is the first ETF to track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has a total fund size exceeding 2 billion yuan as of November 3 [5] - The ETF has an average daily trading volume of 474 million yuan, making it the largest and most liquid ETF tracking this index [5] Index Characteristics - The index has three unique advantages: it exclusively focuses on innovative drug companies, has a high concentration of leading firms with over 71% of the top ten companies, and employs a more reasonable weighting strategy that enhances the proportion of highly active stocks [2][3][4]

Core Insights - Pfizer is showcasing its commitment to the Chinese market and its "China 2030 Strategy" at the 8th China International Import Expo (CIIE), emphasizing its long-term vision and collaboration with China's healthcare ecosystem [2][4][10] - The company has made significant progress in accelerating innovation and enhancing treatment standards in China, with a goal of introducing 60 innovative drugs and new indications by 2030, having already achieved over half of this target [5][6][11] - Pfizer's focus on digital innovation aims to enhance the clinical value and accessibility of its products, integrating advanced digital solutions into the patient journey [7][9] Group 1: Strategic Initiatives - Pfizer's "China 2030 Strategy" was launched to support the high-quality development of China's biopharmaceutical industry, focusing on accelerating innovation and enhancing diagnostic capabilities [5][8] - The company has established strategic partnerships, including a significant collaboration with 3SBio to enhance its oncology pipeline and support local innovations [8][9] - Pfizer's Open Innovation Center in Shanghai and Beijing aims to foster collaboration with local partners, providing comprehensive support throughout the drug development process [9][10] Group 2: Product Development and Innovation - Pfizer is set to introduce its first acute migraine nasal spray, ZavzpretTM, at the CIIE, which offers a new treatment option for migraine patients in China [6][10] - The company has received NDA approvals for several innovative products and new indications, reflecting the increasingly open innovation environment in China [5][6] - Pfizer's commitment to enhancing grassroots medical capabilities is evident through its various projects aimed at standardizing treatment pathways and improving healthcare access [11][12] Group 3: Patient-Centric Approach - Pfizer emphasizes a patient-centered innovation ecosystem, ensuring that patients benefit at every critical juncture of their treatment [6][7] - The company is actively working to reduce the burden of medication costs through collaboration with government and industry partners, exploring innovative payment models [11][12] - Pfizer's initiatives during the CIIE include actions focused on improving treatment standards for specific patient groups, showcasing its dedication to patient care [12]

Core Insights - Pfizer is showcasing its commitment to the Chinese market at the 8th China International Import Expo (CIIE) with the theme "Towards the Future with China" [1] - The company emphasizes its alignment with China's 14th Five-Year Plan and the upcoming 15th Five-Year Plan, focusing on innovation and patient care [3][4] - Pfizer's "China 2030 Strategy" aims to accelerate innovation and enhance healthcare accessibility, with significant progress reported in the past year [4][11] Innovation and Product Development - Pfizer's innovative products are expected to benefit over 42 million patients in China by 2024, with a goal of introducing 60 innovative drugs and new indications by 2030 [4] - The company has already achieved over half of this target, with several products receiving NDA approval in China [4] - The global first acute migraine nasal spray, ZavzpretTM, will be showcased at the expo, highlighting Pfizer's commitment to providing new treatment options [5] Collaboration and Ecosystem Development - Pfizer is focused on fostering local scientific innovation and has established partnerships with nearly ten local collaborators in the past year [7][8] - The launch of the Pfizer R&D Open Innovation Center aims to support local partners throughout the drug development process [8] - Strategic agreements, such as the one with 3SBio, enhance Pfizer's oncology pipeline and demonstrate the global competitiveness of local innovations [7] Commitment to Patient Care - Pfizer is dedicated to improving healthcare quality in China, particularly in rural areas, by promoting standardized treatment protocols [11][12] - The company is actively working to ensure that innovative drugs are accessible to patients, collaborating with government and industry partners to reduce medication costs [12] - Initiatives during the expo will focus on enhancing treatment standards for specific patient groups and exploring sustainable patient support ecosystems [12][13]

Market Overview - On November 3, the Hang Seng Index rose by 0.97%, with southbound trading totaling HKD 106.78 billion, comprising HKD 56.12 billion in buying and HKD 50.65 billion in selling, resulting in a net inflow of HKD 5.47 billion [1][2] Southbound Trading Details - Southbound trading through the Shenzhen Stock Connect recorded a total of HKD 42.40 billion, with buying at HKD 23.29 billion and selling at HKD 19.12 billion, leading to a net inflow of HKD 4.17 billion [1] - The Shanghai Stock Connect saw total trading of HKD 64.38 billion, with buying at HKD 32.84 billion and selling at HKD 31.54 billion, resulting in a net inflow of HKD 1.30 billion [1] Active Stocks - Alibaba-W had the highest trading volume among southbound stocks, totaling HKD 71.45 billion, followed by SMIC and Xiaomi Group-W with HKD 61.52 billion and HKD 51.07 billion respectively [1] - In terms of net buying, Xiaomi Group-W led with a net inflow of HKD 10.29 billion, with China National Offshore Oil Corporation and China Mobile following with net inflows of HKD 9.93 billion and HKD 4.61 billion respectively [1][2] Net Buying and Selling Trends - A total of 7 stocks experienced net buying, with Xiaomi Group-W and China National Offshore Oil Corporation showing significant net buying trends over the past few days, with Xiaomi Group-W having a total net inflow of HKD 19.13 billion over 4 days [2] - Conversely, SMIC recorded the highest net selling at HKD 13.81 billion, with Alibaba-W and Hua Hong Semiconductor also facing significant net selling of HKD 9.56 billion and HKD 6.28 billion respectively [1][2]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The innovative drug market is expected to reignite, with a focus on bottoming out and potential recovery in the sector [5][9] - The report highlights a continuous improvement in Q3 performance, with expectations for further acceleration in 2026 [13][19] - The overall revenue of pharmaceutical companies decreased by 2.0% year-on-year for the first three quarters of 2025, but Q3 showed a 0.6% increase in revenue compared to the previous quarter [19][26] - The report emphasizes the importance of monitoring the innovative drug sector and companies with improving fundamentals for future investment opportunities [4][10] Summary by Sections Industry Performance - In October 2025, the pharmaceutical and biotechnology sector declined by 1.83%, underperforming the CSI 300 index by the same percentage [9][10] - The report notes a mixed performance among sub-sectors, with pharmaceutical commerce and traditional Chinese medicine showing gains, while chemical pharmaceuticals and medical services experienced declines [9][10] Q3 Financial Results - Q3 results indicate a trend of continuous improvement, with revenue growth turning positive for the first time since Q2 2024 [19][26] - The report details that the medical services sector, particularly CRO/CDMO, showed significant performance improvements, while other sectors are still in a clearing phase [19][26] Recommendations - The report recommends focusing on innovative drugs and companies with improving fundamentals, suggesting specific companies such as WuXi AppTec, Innovent Biologics, and others for potential investment [4][10] - It also advises on positioning for 2026, highlighting the expected recovery in demand and orders for CRO/CDMO and medical device companies [4][10]

Group 1 - Southbound funds net bought Hong Kong stocks worth 5.472 billion HKD today [1] - Notable net purchases include Xiaomi Group-W (1.029 billion HKD), China National Offshore Oil Corporation (CNOOC) (999 million HKD), and China Mobile (461 million HKD) [1] - Significant net sales were observed in SMIC (1.381 billion HKD), Alibaba-W (955 million HKD), and Tencent Holdings (151 million HKD) [1] Group 2 - Southbound funds have net bought Xiaomi for four consecutive days, totaling 1.91269 billion HKD [1] - CNOOC has seen net purchases for three consecutive days, amounting to 1.60304 billion HKD [1] - Tencent has experienced net sales for four consecutive days, totaling 1.99056 billion HKD [1]

Core Insights - The Chinese stock market has entered a phase of differentiation following significant meetings and US-China tariff negotiations, with the innovative drug sector showing strong performance [1] - The Hong Kong innovative drug ETF (513120) has seen a year-to-date increase of 91.72%, focusing on high-quality biotech companies in the Hong Kong market [3] - After a strong performance in the first three quarters of the year, the innovative drug sector experienced a brief adjustment but is now regaining upward momentum due to a series of favorable developments [4] Group 1: Major Positive Developments - The annual pharmaceutical procurement has sparked renewed interest in the pharmaceutical and biotech sectors, with negotiations for the 2025 national drug catalog starting on October 30 [5] - This adjustment marks the first inclusion of a "commercial health insurance innovative drug catalog," transitioning from a "basic insurance only" model to a collaborative payment system involving both insurance types [6] - A total of 535 drugs passed the formal review, with 310 generic names seeing a 24.5% increase compared to 2024, indicating a significant rise in interest and potential market expansion [5][6] Group 2: Market Dynamics and Financial Implications - The commercial insurance innovative drug catalog aims to address high-value innovative drugs that basic insurance cannot cover, thus creating a new revenue stream for pharmaceutical companies [6][7] - Predictions suggest that the payment scale for innovative drugs through commercial insurance will rise from 124 billion yuan in 2024 to 440 billion yuan by 2035, a 35-fold increase [7][8] - The innovative drug sector has seen substantial foreign licensing deals, with over $100 billion in total licensing agreements in the first ten months of 2025, surpassing the total for 2024 [13][16] Group 3: Company Performance and Growth - Companies like Innovent Biologics reported a third-quarter revenue exceeding 3.3 billion yuan, reflecting a robust 40% year-on-year growth, driven by strong sales of key products [17] - Other companies, such as Kelun Pharmaceutical and Junshi Biosciences, also reported significant revenue growth, with Kelun's new business segments seeing a 71.87% increase [18] - The overall innovative drug sector is expected to continue its growth trajectory, with an increase in approved innovative drugs and a potential turnaround in profitability by 2026 [18][19] Group 4: Investment Trends - Institutional interest in the biotech innovative drug sector remains high, with a 27.53% share of total holdings in the pharmaceutical industry, reflecting a 2.61 percentage point increase [19] - The Hong Kong innovative drug ETF (513120) has attracted over 10 billion yuan in net inflows in the past ten days, with a total net inflow of over 92.18 billion yuan year-to-date [19][20] - The recent adjustments in the innovative drug sector have led to renewed investment interest, as funds are confident in the sector's future growth potential [21][22]